Warning: The NCBI web site requires JavaScript to function. more...
Automated detection of residual cells after sex-mismatched stem-cell transplantation - evidence for presence of disease-marker negative residual cells.
Erlecke J, Hartmann I, Hoffmann M, Kroll T, Starke H, Heller A, Gloria A, Sayer HG, Johannes T, Claussen U, Liehr T, Loncarevic IF.
Mol Cytogenet. 2009 May 29;2:12.
Related citations
Qualitative assessment of mixed chimerism after allogeneic bone marrow transplantation with regard to leukemic relapse.
Kögler G, Hernandez A, Heyll A, Wolf HH, Wernet P.
Cancer Detect Prev. 1996;20(6):601-9.
FISH analysis of native smears from bone marrow and blood for the monitoring of chimerism and clonal markers after stem cell transplantation in children.
Fuehrer M, Gerusel-Bleck M, Konstantopoulos N, Bender-Goetze C, Walther JU.
Int J Mol Med. 2005 Feb;15(2):291-7.
[Monitoring of bcr/abl fusion gene by interphase-dual-color and dual-fusion fluorescence in situ hybridization in CML after allo-HSCT].
Qian SX, Li JY, Zhang R, Hong M, Qiu HR, Li L, Xu W, Sheng RL, Wu HX.
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2006 Jun;14(3):577-81. Chinese.
[The clinical significance of interphase fluorescence in situ hybridization monitoring chimeric status after sex-mismatched allogeneic hematopoietic stem cell transplantation for leukemia].
Liu Q, Song L, Zhang Y, Wei Y, Xu D, Sun J, Liu X, Xu B, Meng F, Zhou S.
Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2005 Apr;22(2):212-5. Chinese.
Fluorescent in situ hybridization on flow-sorted cells as a tool for evaluating minimal residual disease or chimerism after allogenic bone marrow transplantation.
Cotteret S, Belloc F, Boiron JM, Bilhou-Nabera C, Dumain P, Boyer C, Lacombe F, Reiffers J, Bernard P.
Cytometry. 1998 Oct 15;34(5):216-22.
Simple and reliably sensitive diagnosis and monitoring of Philadelphia chromosome-positive cells in chronic myeloid leukemia by interphase fluorescence in situ hybridization of peripheral blood cells.
Yanagi M, Shinjo K, Takeshita A, Tobita T, Yano K, Kobayashi M, Terasaki H, Naoe T, Ohnishi K, Ohno R.
Leukemia. 1999 Apr;13(4):542-52.
Fluorescence in situ hybridization: a highly efficient technique of molecular diagnosis and predication for disease course in patients with myeloid leukemias.
Amare PS, Baisane C, Saikia T, Nair R, Gawade H, Advani S.
Cancer Genet Cytogenet. 2001 Dec;131(2):125-34.
Distinct patterns of minimal residual disease associated with graft-versus-host disease after allogeneic bone marrow transplantation for chronic myelogenous leukemia.
Pichert G, Roy DC, Gonin R, Alyea EP, Bélanger R, Gyger M, Perreault C, Bonny Y, Lerra I, Murray C, et al.
J Clin Oncol. 1995 Jul;13(7):1704-13.
Early detection of relapse and evaluation of treatment for mixed chimerism using fluorescence in situ hybridization following allogeneic hematopoietic cell transplant for hematological malignancies.
Tamura S, Saheki K, Takatsuka H, Wada H, Fujimori Y, Okamoto T, Takemoto Y, Hashimoto-Tamaoki T, Furuyama J, Kakishita E.
Ann Hematol. 2000 Nov;79(11):622-6.
Molecular analysis of lineage-specific chimerism and minimal residual disease by RT-PCR of p210(BCR-ABL) and p190(BCR-ABL) after allogeneic bone marrow transplantation for chronic myeloid leukemia: increasing mixed myeloid chimerism and p190(BCR-ABL) detection precede cytogenetic relapse.
Serrano J, Roman J, Sanchez J, Jimenez A, Castillejo JA, Herrera C, Gonzalez MG, Reina L, Rodriguez MC, Alvarez MA, Maldonado J, Torres A.
Blood. 2000 Apr 15;95(8):2659-65.
Mixed chimerism of bone marrow vessels (endothelial cells, myofibroblasts) following allogeneic transplantation for chronic myelogenous leukemia.
Kvasnicka HM, Wickenhauser C, Thiele J, Varus E, Hamm K, Beelen DW, Schaefer UW.
Leuk Lymphoma. 2003 Feb;44(2):321-8.
Detection of minimal residual disease using fluorescence DNA in situ hybridization: a follow-up study in leukemia and lymphoma patients.
Nylund SJ, Ruutu T, Saarinen U, Larramendy ML, Knuutila S.
Leukemia. 1994 Apr;8(4):587-94.
Quantitative analysis of chimerism after allogeneic stem cell transplantation by real-time polymerase chain reaction with single nucleotide polymorphisms, standard tandem repeats, and Y-chromosome-specific sequences.
Koldehoff M, Steckel NK, Hlinka M, Beelen DW, Elmaagacli AH.
Am J Hematol. 2006 Oct;81(10):735-46.
Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation.
Pérez-Simón JA, Caballero D, Diez-Campelo M, Lopez-Pérez R, Mateos G, Cañizo C, Vazquez L, Vidriales B, Mateos MV, Gonzalez M, San Miguel JF.
Leukemia. 2002 Aug;16(8):1423-31. Review.
Minimal residual disease is more common in patients who have mixed T-cell chimerism after bone marrow transplantation for chronic myelogenous leukemia.
Mackinnon S, Barnett L, Heller G, O'Reilly RJ.
Blood. 1994 Jun 1;83(11):3409-16.
Combined immunophenotyping and FISH with sex chromosome-specific DNA probes for the detection of chimerism in epidermal Langerhans cells after sex-mismatched bone marrow transplantation.
Hessel H, Mittermüller J, Zitzelsberger H, Weier HU, Bauchinger M.
Histochem Cell Biol. 1996 Nov;106(5):481-5.
Systemic chimerism in sex-mismatched liver transplant recipients detected by fluorescence in situ hybridization.
Nagler A, Ilan Y, Amiel A, Eid A, Tur-Kaspa R.
Transplantation. 1994 May 27;57(10):1458-61.
Detection of mixed chimerism and leukemic relapse after allogeneic bone marrow transplantation in subpopulations of leucocytes by fluorescent in situ hybridization in combination with the simultaneous immunophenotypic analysis of interphase cells.
Kögler G, Wolf HH, Heyll A, Arkesteijn G, Wernet P.
Bone Marrow Transplant. 1995 Jan;15(1):41-8.
Detection of minimal residual disease after sex-mismatch bone marrow transplantation in chronic myelogenous leukemia by fluorescence in situ hybridization.
Nagler A, Slavin S, Yarkoni S, Fejgin M, Amiel A.
Cancer Genet Cytogenet. 1994 Apr;73(2):130-3.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on